Biametrics, MorphoSys to Expand High-Throughput Antibody Screening Collaboration | GenomeWeb

German technology firm Biametrics announced this week that it would expand its relationship with MorphoSys following a successful preliminary study that paired Biametrics' microarray technology with MorphoSys' therapeutic antibodies.

Florian Pröll, managing director at Tübingen-based Biametrics, said in a statement that the company "looks forward to expanding our collaboration in the field of biomolecular interaction analysis" with MorphoSys.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.